Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
A phase 1/2 trial of Vebreltinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.
Overview
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI is a phase 1/2 interventional study registered as NCT06343064 by Avistone Biotechnology Co., Ltd., with 156 participants planned, started 2023-06-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Vebreltinib, PLB1004. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Shares Avistone Biotechnology, Vebreltinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Shares Vebreltinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
- TrialAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
- TrialA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
- TrialA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Shares Vebreltinib, Non-small-cell lung cancer.
- CompanyApollomics